AR017895A1 - Inhibidores del dominio sh2 de la familia src, un metodo para su preparacion, las composiciones farmaceuticas que los contienen, un fragmento deaminoacido que se utiliza para la preparacion de dichos inhibidores, y los metodos biologicos y de tratamiento que los emplean - Google Patents

Inhibidores del dominio sh2 de la familia src, un metodo para su preparacion, las composiciones farmaceuticas que los contienen, un fragmento deaminoacido que se utiliza para la preparacion de dichos inhibidores, y los metodos biologicos y de tratamiento que los emplean

Info

Publication number
AR017895A1
AR017895A1 ARP980106470A ARP980106470A AR017895A1 AR 017895 A1 AR017895 A1 AR 017895A1 AR P980106470 A ARP980106470 A AR P980106470A AR P980106470 A ARP980106470 A AR P980106470A AR 017895 A1 AR017895 A1 AR 017895A1
Authority
AR
Argentina
Prior art keywords
group
heterocyclyl
aryl
alkyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP980106470A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR017895A1 publication Critical patent/AR017895A1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Inhibidores del dominio SH2 de la familia SRC, que responden a la formula (I), en donde: el anillo a se selecciona del grupo que consiste encicloalquilo, arilo o heterociclilo; A se selecciona del grupo que consiste en alquilo, alquenilo, alquinilo,alcoxi, cicloalquilo, cicloalquenilo,heterociclilo y arilo, en donde dicho cicloalquilo, heterociclilo o arilo está opcionalmente enlazada a Q o N a través de un enlazador alcoxi, -O-, amino,alquilo inferior, alquil inferior-amino, carbonilo, amido,amido-alquilo, alcoxicarbonilo, carbonilalquiloxi, cicloalquilo o heterociclilo; Q se seleccionadel grupo que consiste en un enlace >C=O, >S(O)2 y >C=S; B se selecciona del grupo que consiste en H, alquilo inferior y un grupo protector de nitrogeno;Res un enlace o un enlazador alquilo, arilo, heterociclilo o cicloalquilo; C es una funcionalidad de carácter ácido que lleva una o dos cargas negativasa pH fisiologico; D es >CH2, >C=O o >C=S; E es un heterociclo insaturado de seis miembros que tienedos dobles enlaces dentro del anillo y lossiguientes miembros del anillo: (a) uno o dos miembros del anillo de nitrogeno, opcionalmente sustituidos con Rb; (b) un miembro del anillo seleccionadodel grupo que consiste en >C=O, >C=S, >C=NH, >C=N-alquilo inferior y un grupo protector de >C=N-nitrogeno; (c) un miembro del anillo >C-Ra o >N-Ra situado enposicion meta con el punto de union del heterociclo y al nitrogeno adyacente; y (d) dos o tres miembros del anillo de carbono adicionales, en dondedichosmiembros del anillo de carbono adicionales están opcionalmente sustituidos con alquilo, alcoxi, halo, arilo, alquiloxicarbonilo o alquilamino y,si dos miembros del anillo opcionalmente sustituidos están presente en posiciones adyacentes en el heterociclo E, dichos miembros del anillo adyacentes puedenestar enlazados uno con otro para formar un anillo heterocíclico o carboxíclico de 5-8 miembros condensado, que puede ser aromático, parcialmenteinsaturado o totalmente saturado; Ra se selecciona del grupo que consiste en alquilo, alquenilo, alquinilo, heterociclilo, cicloalquilo y arilo, en donde
ARP980106470A 1997-12-18 1998-12-18 Inhibidores del dominio sh2 de la familia src, un metodo para su preparacion, las composiciones farmaceuticas que los contienen, un fragmento deaminoacido que se utiliza para la preparacion de dichos inhibidores, y los metodos biologicos y de tratamiento que los emplean Pending AR017895A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6997197P 1997-12-18 1997-12-18

Publications (1)

Publication Number Publication Date
AR017895A1 true AR017895A1 (es) 2001-10-24

Family

ID=22092332

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980106470A Pending AR017895A1 (es) 1997-12-18 1998-12-18 Inhibidores del dominio sh2 de la familia src, un metodo para su preparacion, las composiciones farmaceuticas que los contienen, un fragmento deaminoacido que se utiliza para la preparacion de dichos inhibidores, y los metodos biologicos y de tratamiento que los emplean

Country Status (13)

Country Link
US (3) US6054470A (es)
EP (1) EP1045836B1 (es)
JP (1) JP4524039B2 (es)
AR (1) AR017895A1 (es)
AT (1) ATE388139T1 (es)
AU (1) AU1719499A (es)
CA (1) CA2315113C (es)
CO (1) CO4990963A1 (es)
DE (1) DE69839221T2 (es)
ES (1) ES2302363T3 (es)
UY (1) UY25313A1 (es)
WO (1) WO1999031066A1 (es)
ZA (1) ZA9811570B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2363689A1 (en) * 1999-04-15 2000-10-26 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as phosphotyrosine mimics
JP2003518129A (ja) 1999-12-22 2003-06-03 メルク フロスト カナダ アンド カンパニー タンパク質チロシンホスファターゼ１ｂ（ｐｔｐ−１ｂ）のインヒビターとなるホスホン酸誘導体
EP1244677A1 (en) 1999-12-22 2002-10-02 Merck Frosst Canada Inc. Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
AU2336001A (en) 1999-12-22 2001-07-03 Merck Frosst Canada & Co. Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
US6777433B2 (en) 1999-12-22 2004-08-17 Merck Frosst Canada & Co. Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
WO2001068655A2 (en) * 2000-03-10 2001-09-20 Ariad Pharmaceuticals, Inc. Caprolactam derivatives and uses thereof
WO2001070754A1 (en) 2000-03-22 2001-09-27 Merck Frosst Canada & Co. Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
KR20030070082A (ko) * 2000-12-28 2003-08-27 시오노기세이야쿠가부시키가이샤 칸나비노이드 2형 수용체 친화 작용을 갖는 피리돈 유도체
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
CA2469435A1 (en) * 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
UA83816C2 (ru) 2003-01-14 2008-08-26 Тева Фармасьютикал Индастриз, Лтд ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ СОДЕРЖИТ ПЕПТИД И ЗАМЕЩЕННЫЙ β-ЦИКЛОДЕКСТРИН, ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКИ
US20050119163A1 (en) * 2003-09-18 2005-06-02 The Government Of The United States Of America, As Represented By The Secretary, SH2 domain binding inhibitors
KR101135765B1 (ko) 2004-03-12 2012-04-23 버텍스 파마슈티칼스 인코포레이티드 아스파르트산 아세탈 카스파아제 억제제의 제조를 위한방법 및 중간체
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN101801951B (zh) 2007-09-14 2013-11-13 杨森制药有限公司 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
RU2510396C2 (ru) 2008-09-02 2014-03-27 Янссен Фармасьютикалз, Инк. 3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов
AU2009319387B2 (en) 2008-11-28 2012-05-10 Addex Pharma S.A. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
WO2010091164A1 (en) * 2009-02-06 2010-08-12 Exelixis, Inc. Inhibitors of glucosylceramide synthase
RS53075B (en) 2009-05-12 2014-04-30 Janssen Pharmaceuticals Inc. 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
JP5707390B2 (ja) 2009-05-12 2015-04-30 ジャンセン ファーマシューティカルズ， インコーポレイテッド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体の正のアロステリック調節因子としてのその使用
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2649069B1 (en) 2010-11-08 2015-08-26 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
WO2014107622A1 (en) 2013-01-07 2014-07-10 University Of Southern California Deoxyuridine triphosphatase inhibitors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
JP6513095B2 (ja) 2014-01-03 2019-05-15 ユニバーシティ オブ サザン カリフォルニア ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤
ES2860298T3 (es) 2014-01-21 2021-10-04 Janssen Pharmaceutica Nv Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
DK3431106T3 (da) 2014-01-21 2021-03-15 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
EP3319939A1 (en) 2015-07-08 2018-05-16 CV6 Therapeutics (NI) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2017006270A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors
US10570100B2 (en) 2015-07-08 2020-02-25 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
US10544105B2 (en) 2015-07-08 2020-01-28 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
WO2018098207A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098209A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
US10858344B2 (en) 2016-11-23 2020-12-08 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098208A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
WO2018098204A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
US11247984B2 (en) 2017-01-05 2022-02-15 Cv6 Therapeutics (Ni) Limited Uracil containing compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0662529B2 (ja) * 1984-07-13 1994-08-17 三共株式会社 アミノ酸誘導体
AU598750B2 (en) * 1985-09-27 1990-07-05 Mitsubishi Chemical Corporation Phenylalanine derivative and proteinase inhibitor
US5580979A (en) * 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
WO1996023813A1 (en) * 1995-02-01 1996-08-08 Affymax Technologies N.V. Peptides and compounds that bind to sh2 domains
EP0727211A1 (en) * 1995-02-10 1996-08-21 Smithkline Beecham Corporation Use of src SH2 specific compounds to treat a bone resorption disease
AU7392696A (en) * 1995-10-04 1997-04-28 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins
WO1997031016A2 (en) * 1996-02-23 1997-08-28 Ariad Pharmaceuticals, Inc. New inhibitors of sh2-mediated processes

Also Published As

Publication number Publication date
JP2003514762A (ja) 2003-04-22
US6268365B1 (en) 2001-07-31
US6284768B1 (en) 2001-09-04
EP1045836B1 (en) 2008-03-05
DE69839221D1 (de) 2008-04-17
JP4524039B2 (ja) 2010-08-11
US6054470A (en) 2000-04-25
ES2302363T3 (es) 2008-07-01
CO4990963A1 (es) 2000-12-26
DE69839221T2 (de) 2009-04-30
UY25313A1 (es) 2000-12-29
CA2315113C (en) 2009-12-08
CA2315113A1 (en) 1999-06-24
ATE388139T1 (de) 2008-03-15
AU1719499A (en) 1999-07-05
EP1045836A1 (en) 2000-10-25
ZA9811570B (en) 1999-09-16
WO1999031066A1 (en) 1999-06-24

Similar Documents

Publication Publication Date Title
AR017895A1 (es) Inhibidores del dominio sh2 de la familia src, un metodo para su preparacion, las composiciones farmaceuticas que los contienen, un fragmento deaminoacido que se utiliza para la preparacion de dichos inhibidores, y los metodos biologicos y de tratamiento que los emplean
EA200400944A1 (ru) Замещенные производные тетрациклина, фармацевтическая композиция и способ лечения субъекта с их использованием
EA200200208A1 (ru) Синергитическая композиция
CY1109558T1 (el) Παραγωγα βενζο[d]αζεπινης για την θεραπεια νευρολογικων διαταραχων
EA200000171A1 (ru) 2-аминопиридины, содержащие в качестве заместителей конденсированные кольца, применяемые в качестве ингибиторов nos (no синтазы)
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
YU70494A (sh) Inhibitori proteinske kinaze c
EA200300171A1 (ru) Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения
EA199900242A1 (ru) Аралкил- и аралкилиден-гетероциклические лактамы и имиды
FI962749A0 (fi) Uusia heterosyklisiä yhdisteitä
EA200100971A1 (ru) Новые соединения и композиции в качестве ингибиторов протеазы
DE60142921D1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
BR0009044A (pt) Composto, composição farmacêutica, método para tratar uma doença em um animal, uso de um composto, e, processo para fabricar um composto
BR0213790A (pt) Derivados de aminobenzamida como inibidores de glicogênio sintase cinase 3beta
ES2191659T3 (es) Derivados heterociclicos substituidos utiles como inhibidores de la agregacion plaquetaria.
AR014554A1 (es) Compuestos polipeptidos, utiles para el tratamiento de infecciones microbianas, procedimiento para prepararlos, composiciones y medicamentos quelos incluyen y el uso de dichos compuestos y metodo para el tratamiento profilactico y terapeutico de infecciones
DE60142313D1 (de) Triptolid-analoga zur behandlung von autoimmunkranheiten und entzündungen
EA200000165A1 (ru) Разветвленные алкоксизамещенные-2-аминопиридины в качестве ингибиторов nos
PT100961A (pt) Oximas de azabiciclo-arilacetileno e -arilenino como agentes colinergicos e composicoes farmaceuticas que as contem
BRPI0411347A (pt) combinações terapêuticas compreendendo inibidores de pde e antagonistas dos receptores de vasopressina para o tratamanento de dismenorréia
EA200100930A1 (ru) Способ лечения хозл
DE69615169D1 (de) N-substituierte azaheterocyclische Carbonsäuren und ihre Alkylester
AR024219A1 (es) COMPUESTOS DE QUINOLONAS 2-(NH- U O-SUSTITUIDAS) UTILES COMO INHIBIDORES DE LA METIONIL t-RNA SINTETASA (MRS) COMPOSICIONES FARMACEUTICAS FORMULADAS CONDICHOS COMPUESTOS; PROCEDIMIENTO PARA SU PREPARACION Y USO DE DICHOS COMPUESTOS PARA PREPARAR MEDICAMENTOS PARA EL TRATAMIENTO DE INFECCIONES BACTER
DE69514100T2 (de) Substituierte kondensierte und verbrückte bicyclische verbindungen als therapeutische mittel
ECSP034891A (es) Derivados de benzoxazepina y su uso como estimula_ dores de receptores ampa